Derek Maetzold Net Worth

The estimated Net Worth of Derek J Maetzold is at least $83.2 Millón dollars as of 9 September 2024. Mr. Maetzold owns over 2,586 units of Castle Biosciences stock worth over $242,220 and over the last 5 years he sold CSTL stock worth over $78,827,728. In addition, he makes $4,132,350 as President, Chief Executive Officer, Founder y Director at Castle Biosciences.

Mr. Maetzold CSTL stock SEC Form 4 insiders trading

Derek has made over 130 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,586 units of CSTL stock worth $76,184 on 9 September 2024.

The largest trade he's ever made was exercising 65,627 units of Castle Biosciences stock on 12 May 2020 worth over $126,004. On average, Derek trades about 12,731 units every 12 days since 2019. As of 9 September 2024 he still owns at least 7,806 units of Castle Biosciences stock.

You can see the complete history of Mr. Maetzold stock trades at the bottom of the page.

Derek Maetzold biography

Derek J. Maetzold serves as President, Chief Executive Officer, Founder, Director of the Company. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.

What is the salary of Derek Maetzold?

As the President, Chief Executive Officer, Founder y Director of Castle Biosciences, the total compensation of Derek Maetzold at Castle Biosciences is $4,132,350. There are no executives at Castle Biosciences getting paid more.

How old is Derek Maetzold?

Derek Maetzold is 58, he's been the President, Chief Executive Officer, Founder y Director of Castle Biosciences since 2017. There are 6 older and 7 younger executives at Castle Biosciences. The oldest executive at Castle Biosciences, Inc. is David Kabakoff, 72, who is the Independent Director.

What's Derek Maetzold's mailing address?

Derek's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX, 77546.

Insiders trading at Castle Biosciences

Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold y Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.

What does Castle Biosciences do?

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Complete history of Mr. Maetzold stock trades at Castle Biosciences

Castle Biosciences executives and stock owners

Castle Biosciences executives and other stock owners filed with the SEC include:

• Derek Maetzold,
  President, Chief Executive Officer, Founder, Director
• Frank Stokes,
  Chief Financial Officer
• Derek J. Maetzold,
  Founder, CEO, Pres & Director
• Frank Stokes,
  Chief Financial Officer
• G. Bradley Cole,
  Independent Director
• Mara Aspinall,
  Independent Director
• Daniel Bradbury,
  Independent Chairman of the Board
• David Kabakoff,
  Independent Director
• Joseph Cook,
  Independent Director
• Miles Harrison,
  Independent Director
• Bernhard Spiess,
  Chief Business Officer
• Noreen Manning,
  Executive Director - Reimbursement
• Michael Maltby,
  Executive Director - Managed Care
• Bob Cook,
  Vice President - Research & Development
• Alice Izzo,
  Vice President - Marketing
• Kristen Oelschlager,
  Senior Vice President - Clinical Operations
• Toby Juvenal,
  Senior Vice President - Sales
• Dr. Robert W. Cook Ph.D.,
  Sr. VP of R&D
• Toby W. Juvenal,
  Chief Commercial Officer
• Camilla Zuckero,
  Exec. Director of Investor Relations & Corp. Communications
• Kristen M. Oelschlager R.N., RN,
  Chief Operating Officer
• Tobin W Juvenal,
  Chief Commercial Officer
• Rodney Cotton,
  Director
• Tiffany Olson,
  Director
• Bonnie H Anderson,
  Director
• Health Quest Partners, L.P....,
  
• Federico A. Monzon,
  Chief Medical Officer
• Venture Partners 2013 Gp, L...,
  
• Kim Caple,
  Director
• Ellen Goldberg,
  Director